Galderma Expands Aesthetics Portfolio with Data-Driven Innovations at AMWC 2026
Event summary
- Galderma will present nine abstracts at AMWC 2026, showcasing scientific data across its aesthetics portfolio.
- New economic modeling data for Relfydess indicates potential annual profit increases for clinics due to faster onset and higher patient satisfaction.
- Sculptra's EU MDR certification expansion allows for body rejuvenation treatments, supported by standardized injection protocols.
- Restylane Lyft demonstrated non-inferiority to a comparator HA injectable for chin profile improvement at Month 3.
The big picture
Galderma's comprehensive presence at AMWC 2026 underscores its commitment to leading the aesthetics industry with innovative, science-based solutions. The company is addressing emerging patient needs such as menopause-related skin changes and regenerative treatments, positioning itself for long-term growth in a rapidly evolving market.
What we're watching
- Market Expansion
- Whether Galderma can sustain its leadership position in the aesthetics market through continuous innovation and addressing emerging needs such as menopause-related skin changes.
- Regulatory Compliance
- The pace at which Sculptra's EU MDR certification will drive adoption of body rejuvenation treatments across multiple markets.
- Competitive Dynamics
- How the economic modeling data for Relfydess will influence clinic adoption rates and competitive positioning against traditional powder toxins.
Related topics